Danahy Kevin Patrick's Form 4 filing
Pulse Biosciences, Inc. (PLSE) · filed Feb 11, 2026
- Accession no.
- 0001437749-26-003840
- Filed
- Feb 11, 2026
- Trade date
- Feb 9-11, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.40M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Danahy Kevin PatrickCIK 0001913245 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | MOption exerciseAcquired | +20,000 | $1.53 | +$30,600 | 63,298 | Direct | |
| Feb 9, 2026 | Common Stock | SSaleDisposed | −20,000 | $21.45F2 | −$429,000 | 43,298 | Direct | |
| Feb 10, 2026 | Common Stock | MOption exerciseAcquired | +20,000 | $1.53 | +$30,600 | 63,298 | Direct | |
| Feb 10, 2026 | Common Stock | SSaleDisposed | −20,000 | $23.52F3 | −$470,400 | 43,298 | Direct | |
| Feb 11, 2026 | Common Stock | MOption exerciseAcquired | +20,000 | $1.53 | +$30,600 | 63,298 | Direct | |
| Feb 11, 2026 | Common Stock | SSaleDisposed | −20,000 | $25.20F4 | −$504,000 | 43,298 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 405,000 | Direct | |
| Feb 10, 2026 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 385,000 | Direct | |
| Feb 11, 2026 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 365,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $21.00 to $23.22 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $26.08 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.36 to $26.36 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.